PTHS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast PTHS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTHS is 66.00 USD with a low forecast of 57.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 23.900

Low

57.00

Averages

66.00

High

75.00

Current: 23.900

Low

57.00

Averages

66.00

High

75.00

Lake Street

NULL

Buy

initiated

$50

2025-12-03

Reason

Lake Street

Price Target

$50

2025-12-03

initiated

NULL

Buy

Reason

Lake Street initiated coverage of Pelthos Therapeutics with a Buy rating and $50 price target.

Lake Street

initiated

$50

2025-12-03

Reason

Lake Street

Price Target

$50

2025-12-03

initiated

Reason

As previously reported, Lake Street initiated coverage of Pelthos Therapeutics with a Buy rating and $50 price target. The July merger of Ligand's Pelthos entities with legacy Channel Therapeutics, alongside a $50M financing and relisting, has effectively recapitalized the company as a commercial-stage, pediatric dermatology and infectious disease-focused company, the analyst tells investors. Zelsuvmi is "the natural first-line choice in molluscum contagiosum" and Pelthos is now adding Xepi, a novel, FDA-approved topical agent for impetigo, into the same pediatric/dermatology call point, giving the company "category-leader potential," the analyst added.

H.C. Wainwright

Buy

initiated

$60

2025-12-03

Reason

H.C. Wainwright

Price Target

$60

2025-12-03

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Pelthos Therapeutics with a Buy rating and $60 price target. Pelthos is a commercial stage biopharma company which launched its first drug, Zelsuvmi in July, the analyst tells investors in a research note. The firm says Zelsuvmi is the first and only at-home treatment indicated for the treatment of molluscum contagiosum, a "large, underserved market." H.C. Wainwright expects continued commercial execution and outperformance on Zelsuvmi to drive share upside in the near term.

Roth Capital

NULL -> Buy

initiated

$57

2025-11-25

Reason

Roth Capital

Price Target

$57

2025-11-25

initiated

NULL -> Buy

Reason

Roth Capital initiated coverage of Pelthos Therapeutics with a Buy rating and $57 price target. The firm sees growing revenue for the company from the Zelsuvmi launch underway and Xepi in late 2026. Pelthos should see momentum in molluscum contagiosum and impetigo, respectively, files to sell common stock, no amount given

Alliance Global

Buy

maintain

$60 -> $75

2025-11-14

Reason

Alliance Global

Price Target

$60 -> $75

2025-11-14

maintain

Buy

Reason

Alliance Global raised the firm's price target on Pelthos Therapeutics to $75 from $60 and keeps a Buy rating on the shares. The company's Q3 report showed progress on the Zelsuvmi launch, the analyst tells investors in a research note. The firm says Zelsuvmi is the only use-at-home treatment for water warts.

Oppenheimer

Outperform

upgrade

$50 -> $57

2025-11-14

Reason

Oppenheimer

Price Target

$50 -> $57

2025-11-14

upgrade

Outperform

Reason

Oppenheimer raised the firm's price target on Pelthos Therapeutics to $57 from $50 and keeps an Outperform rating on the shares following the first financial results as a public company. All attention is on ZELSUVMI with its net revenues of $7.1M, just beating our $6.8M estimate, in the first quarter of its launch, the firm notes. However, Oppenheimer's initial model assumed launch numbers would be supported by significant wholesaler stocking. With stocking a modest factor, the firm increases its Q4 net revenue projection dramatically to $16.2M from $4.5M, supported by October scripts growing over 40% vs. September. The firm does expect the growth rate to taper some entering the holidays.

Valuation Metrics

The current forward P/E ratio for Pelthos Therapeutics Inc (PTHS.A) is -4.36, compared to its 5-year average forward P/E of -8.17. For a more detailed relative valuation and DCF analysis to assess Pelthos Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.17

Current PE

-4.36

Overvalued PE

-3.57

Undervalued PE

-12.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.00

Current EV/EBITDA

-2.20

Overvalued EV/EBITDA

0.49

Undervalued EV/EBITDA

-2.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.01

Current PS

0.86

Overvalued PS

3.79

Undervalued PS

0.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PTHS News & Events

Events Timeline

No data

News

5.0

12-04Globenewswire

Pelthos Launches ZELSUVMI, First FDA-Approved At-Home Treatment for Molluscum Contagiosum

4.0

12-03Benzinga

Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday

8.5

11-07Newsfilter

Pelthos Therapeutics Purchases Xepi® (ozenoxacin) Cream, 1%, and Reveals $18 Million Private Convertible Notes Funding

People Also Watch

Frequently Asked Questions

What is Pelthos Therapeutics Inc (PTHS) stock price today?

The current price of PTHS is 23.9 USD — it has increased 3.96 % in the last trading day.

What is Pelthos Therapeutics Inc (PTHS)'s business?

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi (ozenoxacin) Cream, 1%, which is a non-fluorinated quinolone antimicrobial indicated for the topical treatment of impetigo. The Company is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

What is the price predicton of PTHS Stock?

What is Pelthos Therapeutics Inc (PTHS)'s revenue for the last quarter?

Pelthos Therapeutics Inc revenue for the last quarter amounts to 7.41M USD, decreased % YoY.

What is Pelthos Therapeutics Inc (PTHS)'s earnings per share (EPS) for the last quarter?

Pelthos Therapeutics Inc. EPS for the last quarter amounts to -5.30 USD, increased 80.89 % YoY.

What changes have occurred in the market's expectations for Pelthos Therapeutics Inc (PTHS)'s fundamentals?

The market is revising Upward the revenue expectations for Pelthos Therapeutics Inc. (PTHS) for FY2025, with the revenue forecasts being adjusted by 81.78% over the past three months. During the same period, the stock price has changed by -27.58%.

How many employees does Pelthos Therapeutics Inc (PTHS). have?

Pelthos Therapeutics Inc (PTHS) has 4 emplpoyees as of December 15 2025.

What is Pelthos Therapeutics Inc (PTHS) market cap?

Today PTHS has the market capitalization of 70.96M USD.